NYSE:VNRX VolitionRx (VNRX) Stock Price, News & Analysis $0.73 -0.02 (-2.63%) Closing price 07/28/2025 04:00 PM EasternExtended Trading$0.73 +0.00 (+0.23%) As of 07/28/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About VolitionRx Stock (NYSE:VNRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get VolitionRx alerts:Sign Up Key Stats Today's Range$0.73▼$0.8050-Day Range$0.48▼$0.9252-Week Range$0.40▼$0.94Volume184,487 shsAverage Volume200,102 shsMarket Capitalization$75.94 millionP/E RatioN/ADividend YieldN/APrice Target$3.50Consensus RatingBuy Company Overview VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. Read More VolitionRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreVNRX MarketRank™: VolitionRx scored higher than 31% of companies evaluated by MarketBeat, and ranked 777th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingVolitionRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVolitionRx has only been the subject of 2 research reports in the past 90 days.Read more about VolitionRx's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of VolitionRx is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VolitionRx is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for VNRX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldVolitionRx does not currently pay a dividend.Dividend GrowthVolitionRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for VNRX. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 1 people have searched for VNRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added VolitionRx to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, VolitionRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $48,475.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.40% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 8.09% of the stock of VolitionRx is held by institutions.Read more about VolitionRx's insider trading history. Receive VNRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter. Email Address VNRX Stock News HeadlinesVolitionRx's (VNRX) "Buy" Rating Reaffirmed at D. Boral CapitalJuly 20, 2025 | americanbankingnews.comNu.Q® Discover Expands Global Adoption and Epigenetic InnovationJuly 16, 2025 | prnewswire.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. | Porter & Company (Ad)VolitionRx Limited (VNRX) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comVolition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of NucleosomesJuly 8, 2025 | prnewswire.comVolition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ FailureJune 12, 2025 | prnewswire.comJones Trading Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationJune 11, 2025 | msn.comVolitionRx director Guy Innes buys $10,772 in common stockJune 5, 2025 | investing.comSee More Headlines VNRX Stock Analysis - Frequently Asked Questions How have VNRX shares performed this year? VolitionRx's stock was trading at $0.60 at the start of the year. Since then, VNRX stock has increased by 21.7% and is now trading at $0.7303. How were VolitionRx's earnings last quarter? VolitionRx Limited (NYSE:VNRX) released its earnings results on Monday, March, 25th. The company reported ($0.11) earnings per share for the quarter. The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.50 million. Who are VolitionRx's major shareholders? Top institutional investors of VolitionRx include Silverberg Bernstein Capital Management LLC (0.19%) and Blair William & Co. IL (0.04%). Insiders that own company stock include Cameron John Reynolds, Martin Charles Faulkes, Guy Archibald Innes, Jacob Vincent Micallef, Corp Ltd Eight, Gaetan Michel, Salvatore Thomas Butera, Rodney Gerard Rootsaert and Phillip Barnes. View institutional ownership trends. How do I buy shares of VolitionRx? Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of VolitionRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRx investors own include BlackRock Innovation and Growth Term Trust (BIGZ), FS KKR Capital (FSK), Guggenheim Strategic Opportunities Fund (GOF), 3M (MMM), OFS Credit (OCCI), XAI Octagon Floating Rate & Alternative Income Trust (XFLT) and Broadcom (AVGO). Company Calendar Last Earnings3/25/2024Today7/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Diagnostic substances Sub-IndustryPharmaceutical Products Current SymbolNYSE:VNRX CIK93314 WebN/A Phone646-650-1351Fax65 32 8172 5651Employees80Year FoundedN/APrice Target and Rating Average Price Target for VolitionRx$3.50 High Price Target$5.00 Low Price Target$2.50 Potential Upside/Downside+366.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$35.32 million Net Margins-2,321.14% Pretax Margin-2,346.62% Return on EquityN/A Return on Assets-163.39% Debt Debt-to-Equity RatioN/A Current Ratio0.22 Quick Ratio0.22 Sales & Book Value Annual Sales$1.31 million Price / Sales59.69 Cash FlowN/A Price / Cash FlowN/A Book Value($0.11) per share Price / Book-6.83Miscellaneous Outstanding Shares103,982,000Free Float80,804,000Market Cap$78.09 million OptionableOptionable Beta1.20 The 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (NYSE:VNRX) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VolitionRx Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share VolitionRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.